Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
Purpose: In the treatment of type 2 diabetes mellitus (T2DM), select sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are recommended based on comorbidities such as chronic kidney disease (CKD), heart failure (HF), and atherosclerotic cardiovasc...
Saved in:
Main Authors: | Bethany Murphy, Simran Chahal, Elleigh Shepherd, Nicole Taylor, Austin Camp |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2025-01-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/6432 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01) -
The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01) -
GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01) -
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01) -
Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
by: Mohsina Patwekar, et al.
Published: (2025-01-01)